Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

IASO Biotherapeutics Partners with Brazil’s Butantan Institute to Localize CAR-T Therapy for Hematological Cancers

Fineline Cube Apr 13, 2026
Company Deals

Zhejiang Medicine Plans HKEX Spin-Off of NovoCodex Biopharmaceuticals to Unlock ADC Pipeline Value

Fineline Cube Apr 13, 2026
Company Deals

Haisco Pharma Licenses Nav1.8 Pain Program to AbbVie in $745M Deal, Retaining Greater China Rights

Fineline Cube Apr 13, 2026
Company Deals

Merck KGaA Closes Acquisition of JSR Life Sciences’ Chromatography Business, Bolstering Antibody Purification Portfolio

Fineline Cube Apr 13, 2026
Company Deals Drug

Boehringer Ingelheim and BioNTech Launch Phase Ib/II Trial of Novel T-Cell Engager and Bispecific Antibody Combo for ES-SCLC

Fineline Cube Apr 13, 2026
Policy / Regulatory

Beijing Unveils 32-Point Framework to Accelerate Healthcare Innovation, AI Integration, and Medical Device Development

Fineline Cube Apr 8, 2026
Company Drug

CanSino Biologics Secures NMPA Approval for Pankangxin, China’s First Three-Component Acellular DTaP Vaccine

Fineline Cube Apr 13, 2026
Company Drug

Cutia Therapeutics’ CU-20101 Meets Phase III Endpoints, Demonstrating Non-Inferiority to BOTOX for Glabellar Lines

Fineline Cube Apr 13, 2026
Company Drug

Fujian Cosunter’s Innovative Drug GST-HG141 Exceeds Efficacy in Reducing HBV DNA in Phase II Study

Fineline Cube Aug 12, 2024

Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436), a Chinese pharmaceutical company, has announced the successful...

Company Drug

3SBio Subsidiary Achieves Milestone in Phase III Psoriasis Trial with SSGJ-608

Fineline Cube Aug 12, 2024

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), has announced...

Company Drug

Guangdong Zhongsheng Pharmaceutical’s COVID-19 Drug Leritrelvir Approved in Macau

Fineline Cube Aug 12, 2024

Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317), a pharmaceutical company based in China, has announced...

Company Drug

3SBio’s Subsidiary Achieves Milestone in Phase II Study for Chronic Sinusitis Treatment SSGJ-611

Fineline Cube Aug 12, 2024

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), has announced...

Company Drug

Lee’s Pharma Subsidiary Receives Green Light for Phase III Dry Eye Study and Completes Myopia Trial

Fineline Cube Aug 12, 2024

Lee’s Pharmaceutical Holdings Ltd (HKG: 0950), a prominent Chinese pharmaceutical company, through its subsidiary Zhaoke...

Company

Amgen to Establish New Site in Hyderabad, India, with Focus on Technology and Digital Innovation

Fineline Cube Aug 12, 2024

Amgen (NASDAQ: AMGN), a leading biopharmaceutical company based in the U.S., has announced strategic plans...

Company Deals

MSD to Acquire Curon Biopharmaceutical’s CD3 x CD19 Bispecific Antibody CN201 in USD 1.3 Billion Deal

Fineline Cube Aug 12, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced a strategic acquisition agreement with Shanghai-based...

Company

Sichuan Huiyu Pharmaceutical’s Chairman Ding Zhao Faces CSRC Investigation for Short-Term Stock Trading

Fineline Cube Aug 9, 2024

Sichuan Huiyu Pharmaceutical Co., Ltd (SHA: 688553), a Chinese pharmaceutical company, has disclosed that its...

Company

Fosun Pharma’s West African Project Nears First-Phase Completion, Aims for 5 Billion Drug Units Annually

Fineline Cube Aug 9, 2024

Shanghai Fosun Pharmaceutical Group Co., Ltd (SHA: 600196; HKG: 2196) has announced the anticipated completion...

Company Drug

Jiangsu Hengrui Pharmaceuticals Gains NMPA Approval for Five Drug Candidates, Including IL-17A mAb for Psoriasis

Fineline Cube Aug 9, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a prominent pharmaceutical company in China, has announced...

Company

Innovent Biologics Reports Over RMB 2 Billion in Q2 2024 Sales, Highlighting 50% YOY Growth

Fineline Cube Aug 9, 2024

Innovent Biologics Inc. (HKG: 1801), a leading biopharmaceutical company in China, has reported a significant...

Company Medical Device

Sansure Biotech’s MTHFR Gene Detection Kit Receives NMPA Approval, Aids in Pregnancy Health Management

Fineline Cube Aug 9, 2024

Sansure Biotech Inc. (SHA: 688289), a specialist in molecular diagnostics based in China, has achieved...

Company Drug

Huadong Medicine Expands Global Footprint with Launch of Aesthetic Injection MaiLi in Singapore

Fineline Cube Aug 9, 2024

Huadong Medicine Co., Ltd (SHE: 000963), a Chinese pharmaceutical company, has announced the international expansion...

Company Deals

Harbour BioMed Reclaims Rights to HBM7008 as Cullinan Therapeutics Cancels Licensing Deal

Fineline Cube Aug 9, 2024

Harbour BioMed (HBM), a biopharmaceutical company with operations in the Netherlands, the United States, and...

Company Deals R&D

Wondfo Biotech and University of Science, Malaysia Deepen Ties with Formal Partnership

Fineline Cube Aug 9, 2024

Guangzhou Wondfo Biotech Co., Ltd (SHE: 300482), a biotechnology firm based in China, has formalized...

Company Drug

WestGene Biopharma’s EB Virus-Targeting mRNA Vaccine WGc-043 Clears for Clinical Trials in China

Fineline Cube Aug 9, 2024

WestGene Biopharma Co., Ltd., a biotechnology company based in Chengdu, has received approval from the...

Company Deals

Hansoh Pharmaceutical Secures Rights to Lupeng’s BTK Inhibitor LP-168 in Licensing Deal

Fineline Cube Aug 9, 2024

Jiangsu Hansoh Pharmaceutical Co., Ltd (HKG: 3692), a leading pharmaceutical company based in China, has...

Company Drug

Zelgen Biopharmaceuticals’ ZG006 Earns Orphan Drug Designation from FDA for Small-Cell Lung Cancer

Fineline Cube Aug 9, 2024

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266), a biopharmaceutical company based in China, has announced...

Company

Novo Nordisk Reports 25% YOY Sales Growth in H1 and Q2 2024, Led by GLP-1 Drugs

Fineline Cube Aug 9, 2024

Novo Nordisk (NYSE: NVO), a Danish pharmaceutical giant specializing in diabetes care, has reported its...

Company Legal / IP

Pfizer, Astellas, and University of California Sue Qilu Pharma Over Xtandi Patent Infringement

Fineline Cube Aug 9, 2024

Pfizer Inc. (NYSE: PFE), through its subsidiary Medivation, and co-development partner Astellas Pharma Inc. (TYO:...

Posts pagination

1 … 299 300 301 … 649

Recent updates

  • IASO Biotherapeutics Partners with Brazil’s Butantan Institute to Localize CAR-T Therapy for Hematological Cancers
  • CanSino Biologics Secures NMPA Approval for Pankangxin, China’s First Three-Component Acellular DTaP Vaccine
  • Zhejiang Medicine Plans HKEX Spin-Off of NovoCodex Biopharmaceuticals to Unlock ADC Pipeline Value
  • Cutia Therapeutics’ CU-20101 Meets Phase III Endpoints, Demonstrating Non-Inferiority to BOTOX for Glabellar Lines
  • Hotgen Biotech’s Novel Treg-Targeting Bispecific Antibody SGT003 Clears NMPA Filing Hurdle
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

IASO Biotherapeutics Partners with Brazil’s Butantan Institute to Localize CAR-T Therapy for Hematological Cancers

Company Drug

CanSino Biologics Secures NMPA Approval for Pankangxin, China’s First Three-Component Acellular DTaP Vaccine

Company Deals

Zhejiang Medicine Plans HKEX Spin-Off of NovoCodex Biopharmaceuticals to Unlock ADC Pipeline Value

Company Drug

Cutia Therapeutics’ CU-20101 Meets Phase III Endpoints, Demonstrating Non-Inferiority to BOTOX for Glabellar Lines

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.